Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 8, 2025
Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares
GlobeNewswire
·
May 8, 2025
ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha …
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
GlobeNewswire
·
May 8, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire
·
May 8, 2025
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, …
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
May 8, 2025
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and …
Seamless Therapeutics Expands Board of Directors with Appointment of Alvin Shih
GlobeNewswire
·
May 8, 2025
Dresden, Germany, and Lexington, MA, May 8, 2025 – Seamless Therapeutics, today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board. Dr. Shih is an experienced drug developer and physician with a track record of …
ProQR Announces First Quarter 2025 Operating and Financial Results
GlobeNewswire
·
May 8, 2025
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer …
Fred Ball Joins Axonius Board of Directors to Drive Financial and Global Expansion
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Axonius, the leader in cyber asset management that delivers visibility and actionability across all digital assets, today announced the appointment of Fred Ball to its Board of Directors. Ball, a veteran finance …
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
May 8, 2025
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical …
Surge Copper Delivers Geotechnical Results Supporting Pit Design and Resource Growth at Berg
GlobeNewswire
·
May 8, 2025
PFS-level geotechnical program completed under budget; results support steeper pit walls, lower strip ratio, and highlight resource expansion potential Vancouver, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG) (OTCQB: …
Apyx Medical Corporation Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year Preparing for a planned launch of the AYON™ Body …
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in …
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability …
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients …
Ligand Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
GlobeNewswire
·
May 8, 2025
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …
Entrada Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 …
Verano Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) ("Verano" or the "Company"), a leading multi-state cannabis company, today announced its financial results for the first quarter ended March 31, 2025, which were …
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
GlobeNewswire
·
May 8, 2025
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, …
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 8, 2025
Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025 District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment Fully enrolled Cohort A of ASCENT study in patients with PH-ILD Further strengthened …
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
GlobeNewswire
·
May 8, 2025
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b …